# Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

> **NCT05998135** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 28 (estimated)

## Conditions studied

- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Resistant Ovarian Carcinoma

## Interventions

- **DRUG:** Atovaquone
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Paracentesis

## Key facts

- **NCT ID:** NCT05998135
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998135, "Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05998135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*